Inventor · disambiguated record
Stephen B. Shrewsbury
Also filed as: SHREWSBURY STEPHEN B
8 granted patents·12 pending applications·72 citations·filing 2008–2023
86Inventor score
Files withMAP PHARMACEUTICALS INC7IMPEL NEUROPHARMA INC4IMPEL PHARMACEUTICALS INC4COOK ROBERT O3SHREWSBURY STEPHEN B1
Top patents by PatentIndex Score
20 records- 0195US7994197B2Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profileMAP PHARMACEUTICALS INC·Filed 2009·Granted Aug 9, 2011·28 cites·32 claims
- 0294US8119639B2Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profileCOOK ROBERT O·Filed 2010·Granted Feb 21, 2012·28 cites·14 claims
- 0389US8148377B2Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profileCOOK ROBERT O·Filed 2008·Granted Apr 3, 2012·9 cites·25 claims
- 0488US11185497B2Intranasal delivery of dihydroergotamine by precision olfactory deviceIMPEL NEUROPHARMA INC·Filed 2020·Granted Nov 30, 2021·2 cites·5 claims
- 0587US9833451B2Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profileMAP PHARMACEUTICALS INC·Filed 2015·Granted Dec 5, 2017·4 cites·4 claims
- 0678US10172853B2Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profileMAP PHARMACEUTICALS INC·Filed 2017·Granted Jan 8, 2019·1 cites·17 claims
- 0771US2020352939A1Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profileMAP PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 0871US2024252489A1Repeated administration of dihydroergotamine for treatment of frequent migraine headachesWOODWARD SPECIALTY LLC·Filed 2023·Application pending·0 cites
- 0970US2023301955A1Respiratory tract delivery of levodopa and dopa decarboxylase inhibitor for treatment of parkinson's diseaseIMPEL PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1069US11690819B2Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's diseaseIMPEL PHARMACEUTICALS INC·Filed 2022·Granted Jul 4, 2023·0 cites·18 claims
- 1169US2009149432A1Methods for administering corticosteroid formulationsSHREWSBURY STEPHEN B·Filed 2008·Application pending·0 cites
- 1268US11517548B2Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's DiseaseIMPEL PHARMACEUTICALS INC·Filed 2019·Granted Dec 6, 2022·0 cites·15 claims
- 1368US2019247393A1Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profileMAP PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1468US2022105030A1Intranasal delivery of dihydroergotamine by precision olfactory deviceIMPEL NEUROPHARMA INC·Filed 2021·Application pending·0 cites
- 1566US2015057287A1Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profileMAP PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1660US2012245179A1Method Of Therapeutic Administration of DHE To Enable Rapid Relief Of Migraine While Minimizing Side Effect ProfileCOOK ROBERT O·Filed 2012·Application pending·0 cites
- 1758US2021236485A1Repeated administration of dihydroergotamine for treatment of frequent migraine headachesIMPEL NEUROPHARMA INC·Filed 2021·Application pending·0 cites
- 1856US2019209463A1Intranasal delivery of dihydroergotamine by precision olfactory deviceIMPEL NEUROPHARMA INC·Filed 2019·Application pending·0 cites
- 1954US2022296504A1Intranasal delivery of levodopa powder by precision olfactory deviceIMPEL PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2052US2014323451A1Methods for administering corticosteroid formulationsMAP PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stephen B. Shrewsbury files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →